Skip to main content
Premium Trial:

Request an Annual Quote

Eilaf Distributing Saladax's My5-FU Test in Egypt, Other Parts of Middle East

NEW YORK (GenomeWeb News) – Saladax Biomedical said today that Eilaf Pharma will exclusively distribute the My5-FU diagnostic test in Egypt and the Middle East North African region.

Saladax's test allows physicians to determine optimal dosing of the 5-fluorouracil (5-FU) anti-cancer drug for patients, and is the first of the Bethlehem, Penn.-based firm's dose management tests to be commercially available.

5-FU is a chemotherapy widely used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors, Saladax said.

"We hope that with this tool, our oncologists will be able to provide their patients with the most appropriate course of chemotherapy possible," Haytham Abuelfadl, Eilaf's managing director, said in a statement.

Financial and other terms were not disclosed.

Saladax has inked several distribution deals for My5-FU in the past year, and most recently signed on InyDia Labs to distribute the test in Spain and Portugal.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.